Aspen Neuroscience Inc. Company Profile
NASDAQ: ASPEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Aspen Neuroscience at a glance
Aspen Neuroscience Inc. (NASDAQ: ASPE) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Diego, CA. Aspen Neuroscience is led by Dr. Damien McDevitt Ph.D. and employs about 120 people. The company's shares have traded publicly since 2026.
At a market capitalization of $360.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002124080, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Aspen Neuroscience do?
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018. Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- Aspen Neuroscience Inc.
- Ticker
- NASDAQ: ASPE
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Damien McDevitt Ph.D.
- Employees
- 120
- Headquarters
- 10835 Road to the Cure, San Diego, CA, United States
- Phone
- (858) 263-1222
- Website
- aspenneuroscience.com
- IPO year
- 2026
- Market cap
- $360.28M
- SEC CIK
- 0002124080
Companies similar to Aspen Neuroscience
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PEPGPepGen Inc. | 3.78 | -3.82% | $356.31M | vs ASPE |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs ASPE |
| PHATPhathom Pharmaceuticals Inc. | 4.66 | -8.27% | $378.82M | vs ASPE |
| CTNMContineum Therapeutics Inc. Class A | 8.68 | -3.98% | $340.83M | vs ASPE |
| IRDOpus Genetics Inc. | 3.99 | -2.21% | $385.65M | vs ASPE |
| MPLTMapLight Therapeutics Inc. | 5.94 | -7.48% | $330.12M | vs ASPE |
| AVTXAvalo Therapeutics Inc. | 6.76 | +0.15% | $390.88M | vs ASPE |
| INOInovio Pharmaceuticals Inc. | 1.76 | +2.92% | $329.66M | vs ASPE |